Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
US Army
Teva
Citi
Covington

Generated: August 21, 2019

DrugPatentWatch Database Preview

Patent: 8,119,417

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,119,417
Title:Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples
Abstract: Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.
Inventor(s): Roder; Heinrich (Steamboat Springs, CO), Tsypin; Maxim (Steamboat Springs, CO), Grigorieva; Julia (Steamboat Springs, CO)
Assignee: Biodesix, Inc. (Broomfield, CO)
Application Number:12/931,322
Patent Claims:see list of patent claims

Details for Patent 8,119,417

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Biodesix, Inc. (Broomfield, CO) 2026-03-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,119,417

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2007126758 Jan 10, 2008
World Intellectual Property Organization (WIPO) 2007126758 Nov 08, 2007
World Intellectual Property Organization (WIPO) 2010085234 Jul 29, 2010
World Intellectual Property Organization (WIPO) 2010085235 Jul 29, 2010
United States of America 2007231921 Oct 04, 2007
United States of America 2008306898 Dec 11, 2008
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Harvard Business School
Fuji
Johnson and Johnson
Citi
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.